With the beginning of the DT trials, my assumptions are that there will now be increasing numbers of patients receiving the LVAD in both the US trials, Eurpoean trials and commercially in Australia. Assuming also that the trials are positive as they progress there will be increasing sales and income and also improving reputation, PR and marketing in the cardiac health area.
I know that amny punters have been hurt by the falling sp but it looks to me that the company is now on the path to profitablility and the sp should climb in accordance.
VCR
ventracor limited
